FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890930659> ?p ?o ?g. }

• W2890930659 endingPage "2213" @default.
• W2890930659 startingPage "2208" @default.
• W2890930659 abstract "BackgroundA nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of this Q4W regimen were based on population pharmacokinetic (PK) analyses, established flat exposure–response relationships, and clinical safety. The objective of this study was to compare the PK exposure of 480 mg Q4W with 3 mg/kg every 2 weeks (Q2W) and 240 mg Q2W using modeling and simulation, and to evaluate clinical safety of the Q4W regimen.Patients and methodsNivolumab PK exposure for the 480 mg Q4W schedule was simulated for 3817 patients across multiple tumor types and compared with those for the 3 mg/kg Q2W and 240 mg Q2W schedules. The safety profile of the Q4W schedule was assessed by analysis of clinical data from 61 patients who transitioned to nivolumab 480 mg Q4W from 3 mg/kg Q2W during four phase III clinical trials.ResultsCompared with 3 mg/kg Q2W, nivolumab 480 mg Q4W produced similar time-averaged concentration, approximately 16% lower trough concentration, and 45% higher peak concentration at steady state. The peak concentration for 480 mg Q4W was significantly lower than that of 10 mg/kg Q2W, a dose previously shown to have an acceptable tolerability and safety profile. Treatment-related adverse events (TRAEs) that started after transitioning from 3 mg/kg Q2W to 480 mg Q4W were reported in 14.8% of patients, with 1.6% of patients reporting grades 3–4 TRAEs. Pooled safety data for these patients are consistent with those for the 3 mg/kg Q2W schedules, and no new safety signals were identified.ConclusionsThe time-averaged steady-state exposure and safety profile of nivolumab 480 mg Q4W are consistent with that of 3 mg/kg Q2W across multiple tumor types. Nivolumab 480 mg Q4W represents a new dosing schedule option, and in addition to 240 mg Q2W, provides convenience and flexibility for patient care.Clinical trial numbersNCT01721772, NCT01668784, NCT01673867, NCT01642004" @default.
• W2890930659 created "2018-09-27" @default.
• W2890930659 creator A5001548963 @default.
• W2890930659 creator A5001901126 @default.
• W2890930659 creator A5011152885 @default.
• W2890930659 creator A5042806250 @default.
• W2890930659 creator A5056861119 @default.
• W2890930659 creator A5060207140 @default.
• W2890930659 creator A5067036952 @default.
• W2890930659 creator A5067734724 @default.
• W2890930659 creator A5071577704 @default.
• W2890930659 creator A5072754070 @default.
• W2890930659 creator A5078083181 @default.
• W2890930659 creator A5078545719 @default.
• W2890930659 date "2018-11-01" @default.
• W2890930659 modified "2023-10-15" @default.
• W2890930659 title "Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer" @default.
• W2890930659 cites W2093849386 @default.
• W2890930659 cites W2104347254 @default.
• W2890930659 cites W2128035403 @default.
• W2890930659 cites W2132779754 @default.
• W2890930659 cites W2156353875 @default.
• W2890930659 cites W2160834915 @default.
• W2890930659 cites W2222086386 @default.
• W2890930659 cites W2303758877 @default.
• W2890930659 cites W2549481046 @default.
• W2890930659 cites W2567068937 @default.
• W2890930659 cites W2612703804 @default.
• W2890930659 cites W2615652585 @default.
• W2890930659 cites W2754947201 @default.
• W2890930659 cites W2775344839 @default.
• W2890930659 doi "https://doi.org/10.1093/annonc/mdy408" @default.
• W2890930659 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6290887" @default.
• W2890930659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30215677" @default.
• W2890930659 hasPublicationYear "2018" @default.
• W2890930659 type Work @default.
• W2890930659 sameAs 2890930659 @default.
• W2890930659 citedByCount "126" @default.
• W2890930659 countsByYear W28909306592018 @default.
• W2890930659 countsByYear W28909306592019 @default.
• W2890930659 countsByYear W28909306592020 @default.
• W2890930659 countsByYear W28909306592021 @default.
• W2890930659 countsByYear W28909306592022 @default.
• W2890930659 countsByYear W28909306592023 @default.
• W2890930659 crossrefType "journal-article" @default.
• W2890930659 hasAuthorship W2890930659A5001548963 @default.
• W2890930659 hasAuthorship W2890930659A5001901126 @default.
• W2890930659 hasAuthorship W2890930659A5011152885 @default.
• W2890930659 hasAuthorship W2890930659A5042806250 @default.
• W2890930659 hasAuthorship W2890930659A5056861119 @default.
• W2890930659 hasAuthorship W2890930659A5060207140 @default.
• W2890930659 hasAuthorship W2890930659A5067036952 @default.
• W2890930659 hasAuthorship W2890930659A5067734724 @default.
• W2890930659 hasAuthorship W2890930659A5071577704 @default.
• W2890930659 hasAuthorship W2890930659A5072754070 @default.
• W2890930659 hasAuthorship W2890930659A5078083181 @default.
• W2890930659 hasAuthorship W2890930659A5078545719 @default.
• W2890930659 hasBestOaLocation W28909306591 @default.
• W2890930659 hasConcept C111919701 @default.
• W2890930659 hasConcept C112705442 @default.
• W2890930659 hasConcept C121608353 @default.
• W2890930659 hasConcept C126322002 @default.
• W2890930659 hasConcept C197934379 @default.
• W2890930659 hasConcept C2777288759 @default.
• W2890930659 hasConcept C2777701055 @default.
• W2890930659 hasConcept C2778375690 @default.
• W2890930659 hasConcept C2780030458 @default.
• W2890930659 hasConcept C2781413609 @default.
• W2890930659 hasConcept C2908647359 @default.
• W2890930659 hasConcept C3018359032 @default.
• W2890930659 hasConcept C41008148 @default.
• W2890930659 hasConcept C535046627 @default.
• W2890930659 hasConcept C68387754 @default.
• W2890930659 hasConcept C71924100 @default.
• W2890930659 hasConcept C98274493 @default.
• W2890930659 hasConcept C99454951 @default.
• W2890930659 hasConceptScore W2890930659C111919701 @default.
• W2890930659 hasConceptScore W2890930659C112705442 @default.
• W2890930659 hasConceptScore W2890930659C121608353 @default.
• W2890930659 hasConceptScore W2890930659C126322002 @default.
• W2890930659 hasConceptScore W2890930659C197934379 @default.
• W2890930659 hasConceptScore W2890930659C2777288759 @default.
• W2890930659 hasConceptScore W2890930659C2777701055 @default.
• W2890930659 hasConceptScore W2890930659C2778375690 @default.
• W2890930659 hasConceptScore W2890930659C2780030458 @default.
• W2890930659 hasConceptScore W2890930659C2781413609 @default.
• W2890930659 hasConceptScore W2890930659C2908647359 @default.
• W2890930659 hasConceptScore W2890930659C3018359032 @default.
• W2890930659 hasConceptScore W2890930659C41008148 @default.
• W2890930659 hasConceptScore W2890930659C535046627 @default.
• W2890930659 hasConceptScore W2890930659C68387754 @default.
• W2890930659 hasConceptScore W2890930659C71924100 @default.
• W2890930659 hasConceptScore W2890930659C98274493 @default.
• W2890930659 hasConceptScore W2890930659C99454951 @default.
• W2890930659 hasFunder F4320307115 @default.
• W2890930659 hasIssue "11" @default.
• W2890930659 hasLocation W28909306591 @default.
• W2890930659 hasLocation W28909306592 @default.

• next